Tag: CAB-LA
-
England and Wales Set to Welcome HIV-Prevention Jab CAB-LA as Game-Changing PrEP Option
Overview: A new chapter in HIV prevention A potential breakthrough in the fight against HIV is on the cusp of becoming standard care in England and Wales. Cabotegravir, known as CAB-LA, is an injectable pre-exposure prophylaxis (PrEP) option that could be administered every two months to reduce the risk of HIV infection among HIV-negative adults…
-
New HIV Prevention Jab Set to Transform PrEP in England and Wales
Overview: A New Chapter in HIV Prevention A long-awaited option for preventing HIV infection is moving closer to routine use in England and Wales. Cabotegravir (CAB-LA), a long-acting injectable that is administered every two months, is poised to become the first injectable form of PrEP (pre-exposure prophylaxis) approved by the National Institute for Health and…
-
England and Wales poised to approve game-changing HIV prevention jab
New injectable PrEP set to reshape HIV prevention England and Wales are nearing a landmark decision that could alter the landscape of HIV prevention. A long-acting injectable drug, cabotegravir (CAB-LA), is recommended for use in adults and young people who are HIV-negative, with the aim of reducing new infections. Unlike the routine daily tablets used…